JSB Market Research: Schizophrenia - Pipeline Review, H1 2014
This report "Schizophrenia - Pipeline Review, H1 2014'' provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
This report "Schizophrenia - Pipeline Review, H1 2014'' provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> <strong>Review</strong>, <strong>H1</strong> <strong>2014</strong><br />
On 8 th July <strong>2014</strong><br />
Summary<br />
This report "<strong>Schizophrenia</strong> - <strong>Pipeline</strong> <strong>Review</strong>, <strong>H1</strong> <strong>2014</strong>'' provides comprehensive information on<br />
the therapeutic development for <strong>Schizophrenia</strong>, complete with comparative analysis at various<br />
stages, therapeutics assessment by drug target, mechanism of action (MoA), route of<br />
administration (RoA) and molecule type, along with latest updates, and featured news and<br />
press releases. It also reviews key players involved in the therapeutic development for<br />
<strong>Schizophrenia</strong> and special features on late-stage and discontinued projects.<br />
Browse Full Report @ http://www.jsbmarketresearch.com/healthcare-medical/r-<br />
<strong>Schizophrenia</strong>-<strong>Pipeline</strong>-<strong>Review</strong>-118888<br />
Global <strong>Market</strong>s Direct’s report features investigational drugs from across globe covering over<br />
20 therapy areas and nearly 3,000 indications. The report is built using data and information<br />
sourced from Global <strong>Market</strong>s Direct’s proprietary databases, Company/University websites, SEC<br />
filings, investor presentations and featured press releases from company/university sites and<br />
industry-specific third party sources, put together by Global <strong>Market</strong>s Direct’s team. Drug<br />
profiles/records featured in the report undergoes periodic updation following a stringent set of<br />
processes that ensures that all the profiles are updated with the latest set of information.<br />
Additionally, processes including live news & deals tracking, browser based alert-box and<br />
clinical trials registries tracking ensure that the most recent developments are captured on a<br />
real time basis.<br />
The report enhances decision making capabilities and help to create effective counter strategies<br />
to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and<br />
MOAs to produce first-in-class and best-in-class products.<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
Note*: Certain sections in the report may be removed or altered based on the availability and<br />
relevance of data for the indicated disease.<br />
Scope<br />
- The report provides a snapshot of the global therapeutic landscape of <strong>Schizophrenia</strong><br />
- The report reviews key pipeline products under drug profile section which includes, product<br />
description, MoA and R&D brief, licensing and collaboration details & other developmental<br />
activities<br />
- The report reviews key players involved in the therapeutics development for <strong>Schizophrenia</strong><br />
and enlists all their major and minor projects<br />
- The report summarizes all the dormant and discontinued pipeline projects<br />
- A review of the <strong>Schizophrenia</strong> products under development by companies and<br />
universities/research institutes based on information derived from company and industryspecific<br />
sources<br />
- <strong>Pipeline</strong> products coverage based on various stages of development ranging from preregistration<br />
till discovery and undisclosed stages<br />
- A detailed assessment of monotherapy and combination therapy pipeline projects<br />
- Coverage of the <strong>Schizophrenia</strong> pipeline on the basis of target, MoA, route of administration<br />
and molecule type<br />
- Latest news and deals relating related to pipeline products<br />
Reasons to buy<br />
- Provides strategically significant competitor information, analysis, and insights to formulate<br />
effective R&D development strategies<br />
- Identify emerging players with potentially strong product portfolio and create effective<br />
counter-strategies to gain competitive advantage<br />
- Develop strategic initiatives by understanding the focus areas of leading companies<br />
- Identify and understand important and diverse types of therapeutics under development for<br />
<strong>Schizophrenia</strong><br />
- Plan mergers and acquisitions effectively by identifying key players of the most promising<br />
pipeline<br />
- Devise corrective measures for pipeline projects by understanding <strong>Schizophrenia</strong> pipeline<br />
depth and focus of Indication therapeutics<br />
- Develop and design in-licensing and out-licensing strategies by identifying prospective<br />
partners with the most attractive projects to enhance and expand business potential and scope<br />
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
factors that drove them from pipeline<br />
Other industries we cover:<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Advertising and Media<br />
Automotive and Parts<br />
Consumer Goods<br />
Healthcare and Medical<br />
Finance and Banking<br />
Food and Beverages<br />
Travel and Tourism<br />
Textiles and Clothing<br />
SWOT Analysis<br />
Table of Content<br />
Introduction 7<br />
<strong>Schizophrenia</strong> Overview 8<br />
Therapeutics Development 9<br />
<strong>Schizophrenia</strong> - Therapeutics under Development by Companies 11<br />
<strong>Schizophrenia</strong> - Therapeutics under Investigation by Universities/Institutes 18<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> Products Glance 20<br />
<strong>Schizophrenia</strong> - Products under Development by Companies 24<br />
<strong>Schizophrenia</strong> - Products under Investigation by Universities/Institutes 33<br />
<strong>Schizophrenia</strong> - Companies Involved in Therapeutics Development 34<br />
<strong>Schizophrenia</strong> - Therapeutics Assessment 113<br />
Drug Profiles 134<br />
<strong>Schizophrenia</strong> - Recent <strong>Pipeline</strong> Updates 319<br />
<strong>Schizophrenia</strong> - Dormant Projects 359<br />
<strong>Schizophrenia</strong> - Discontinued Products 362<br />
<strong>Schizophrenia</strong> - Product Development Milestones 363<br />
Appendix 372<br />
List of Tables<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
Number of Products under Development for <strong>Schizophrenia</strong>, <strong>H1</strong> <strong>2014</strong> 25<br />
Number of Products under Development for <strong>Schizophrenia</strong> - Comparative Analysis, <strong>H1</strong> <strong>2014</strong> 26<br />
Number of Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> 28<br />
Number of Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> (Contd..1) 29<br />
Number of Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> (Contd..2) 30<br />
Number of Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> (Contd..3) 31<br />
Number of Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> (Contd..4) 32<br />
Number of Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> (Contd..5) 33<br />
Number of Products under Investigation by Universities/Institutes, <strong>H1</strong> <strong>2014</strong> 35<br />
Comparative Analysis by Late Stage Development, <strong>H1</strong> <strong>2014</strong> 36<br />
Comparative Analysis by Clinical Stage Development, <strong>H1</strong> <strong>2014</strong> 37<br />
Comparative Analysis by Early Stage Development, <strong>H1</strong> <strong>2014</strong> 38<br />
Comparative Analysis by Unknown Stage Development, <strong>H1</strong> <strong>2014</strong> 39<br />
Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> 40<br />
Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> (Contd..1) 41<br />
Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> (Contd..2) 42<br />
Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> (Contd..3) 43<br />
Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> (Contd..4) 44<br />
Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> (Contd..5) 45<br />
Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> (Contd..6) 46<br />
Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> (Contd..7) 47<br />
Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> (Contd..8) 48<br />
Products under Investigation by Universities/Institutes, <strong>H1</strong> <strong>2014</strong> 49<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Bristol-Myers Squibb Company, <strong>H1</strong> <strong>2014</strong> 50<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Johnson & Johnson, <strong>H1</strong> <strong>2014</strong> 51<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Boehringer Ingelheim GmbH, <strong>H1</strong> <strong>2014</strong> 52<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by F. Hoffmann-La Roche Ltd., <strong>H1</strong> <strong>2014</strong> 53<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Eli Lilly and Company, <strong>H1</strong> <strong>2014</strong> 54<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Athersys, Inc., <strong>H1</strong> <strong>2014</strong> 55<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Alkermes Plc, <strong>H1</strong> <strong>2014</strong> 56<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Merck & Co., Inc., <strong>H1</strong> <strong>2014</strong> 57<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Dainippon Sumitomo Pharma Co., Ltd., <strong>H1</strong> <strong>2014</strong> 58<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Taisho Pharmaceutical Co., Ltd., <strong>H1</strong> <strong>2014</strong> 59<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by NeuroDerm Ltd., <strong>H1</strong> <strong>2014</strong> 60<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Takeda Pharmaceutical Company Limited, <strong>H1</strong> <strong>2014</strong> 61<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Zogenix, Inc., <strong>H1</strong> <strong>2014</strong> 62<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Neurocrine Biosciences, Inc., <strong>H1</strong> <strong>2014</strong> 63<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Novartis AG, <strong>H1</strong> <strong>2014</strong> 64<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by EnVivo Pharmaceuticals, <strong>H1</strong> <strong>2014</strong> 65<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Astellas Pharma Inc., <strong>H1</strong> <strong>2014</strong> 66<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Egis Gyogyszergyar Nyrt, <strong>H1</strong> <strong>2014</strong> 67<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Richter Gedeon Nyrt., <strong>H1</strong> <strong>2014</strong> 68<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by H. Lundbeck A/S, <strong>H1</strong> <strong>2014</strong> 69<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Les Laboratoires Servier SAS, <strong>H1</strong> <strong>2014</strong> 70<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Mitsubishi Tanabe Pharma Corporation, <strong>H1</strong> <strong>2014</strong> 71<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Pfizer Inc., <strong>H1</strong> <strong>2014</strong> 72<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Teva Pharmaceutical Industries Limited, <strong>H1</strong> <strong>2014</strong> 73<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Zydus Cadila Healthcare Limited, <strong>H1</strong> <strong>2014</strong> 74<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by XTL Biopharmaceuticals Ltd., <strong>H1</strong> <strong>2014</strong> 75<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by NuPathe Inc., <strong>H1</strong> <strong>2014</strong> 76<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Addex Therapeutics, <strong>H1</strong> <strong>2014</strong> 77<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Evotec AG, <strong>H1</strong> <strong>2014</strong> 78<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by GW Pharmaceuticals plc, <strong>H1</strong> <strong>2014</strong> 79<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Bionomics Limited, <strong>H1</strong> <strong>2014</strong> 80<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Acadia Pharmaceuticals Inc., <strong>H1</strong> <strong>2014</strong> 81<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Dongwha Pharm Co., Ltd., <strong>H1</strong> <strong>2014</strong> 82<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Biotie Therapies Corp., <strong>H1</strong> <strong>2014</strong> 83<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Suven Life Sciences Ltd., <strong>H1</strong> <strong>2014</strong> 84<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Newron Pharmaceuticals S.p.A., <strong>H1</strong> <strong>2014</strong> 85<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Jiangsu Nhwa Pharma Corporation, <strong>H1</strong> <strong>2014</strong> 86<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Snowdon Inc., <strong>H1</strong> <strong>2014</strong> 87<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Domain Therapeutics SA, <strong>H1</strong> <strong>2014</strong> 88<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Critical Pharmaceuticals Limited, <strong>H1</strong> <strong>2014</strong> 89<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Curemark, LLC, <strong>H1</strong> <strong>2014</strong> 90<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by AGY Therapeutics, Inc., <strong>H1</strong> <strong>2014</strong> 91<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Fabre-Kramer Pharmaceuticals, Inc., <strong>H1</strong> <strong>2014</strong> 92<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by GP Pharm, S.A., <strong>H1</strong> <strong>2014</strong> 93<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Omeros Corporation, <strong>H1</strong> <strong>2014</strong> 94<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Laboratorios Farmaceuticos Rovi, S.A., <strong>H1</strong> <strong>2014</strong> 95<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Intra-Cellular Therapies, Inc., <strong>H1</strong> <strong>2014</strong> 96<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Peptron, Inc., <strong>H1</strong> <strong>2014</strong> 97<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Targacept, Inc., <strong>H1</strong> <strong>2014</strong> 98<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Vanda Pharmaceuticals Inc., <strong>H1</strong> <strong>2014</strong> 99<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Galenea Corp., <strong>H1</strong> <strong>2014</strong> 100<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Adamed Sp. z o.o., <strong>H1</strong> <strong>2014</strong> 101<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by KemPharm, Inc., <strong>H1</strong> <strong>2014</strong> 102<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Heptares Therapeutics Ltd., <strong>H1</strong> <strong>2014</strong> 103<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Ascendis Pharma A/S, <strong>H1</strong> <strong>2014</strong> 104<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Otsuka Holdings Co., Ltd., <strong>H1</strong> <strong>2014</strong> 105<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by BIOPROJET SCR, <strong>H1</strong> <strong>2014</strong> 106<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Reviva Pharmaceuticals Inc., <strong>H1</strong> <strong>2014</strong> 107<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Promentis Pharmaceuticals, Inc., <strong>H1</strong> <strong>2014</strong> 108<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Naurex, Inc., <strong>H1</strong> <strong>2014</strong> 109<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Acino Pharma AG, <strong>H1</strong> <strong>2014</strong> 110<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by PharmaNeuroBoost NV, <strong>H1</strong> <strong>2014</strong> 111<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by GeNeuro SA, <strong>H1</strong> <strong>2014</strong> 112<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Delpor, Inc., <strong>H1</strong> <strong>2014</strong> 113<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Mnemosyne Pharmaceuticals, Inc., <strong>H1</strong> <strong>2014</strong> 114<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Aestus Therapeutics, Inc., <strong>H1</strong> <strong>2014</strong> 115<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Rottapharm|Madaus, <strong>H1</strong> <strong>2014</strong> 116<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Sunovion Pharmaceuticals Inc., <strong>H1</strong> <strong>2014</strong> 117<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by BioCrea GmbH, <strong>H1</strong> <strong>2014</strong> 118<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Lead Discovery Center GmbH, <strong>H1</strong> <strong>2014</strong> 119<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by BRAINco Biopharma, S.L., <strong>H1</strong> <strong>2014</strong> 120<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Echo Pharmaceuticals B.V., <strong>H1</strong> <strong>2014</strong> 121<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Cerecor Inc., <strong>H1</strong> <strong>2014</strong> 122<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Karuna Pharmaceuticals Inc., <strong>H1</strong> <strong>2014</strong> 123<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by SK Biopharmaceuticals Co., Ltd., <strong>H1</strong> <strong>2014</strong> 124<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Sage Therapeutics, <strong>H1</strong> <strong>2014</strong> 125<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by AbbVie Inc., <strong>H1</strong> <strong>2014</strong> 126<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Angita B.V., <strong>H1</strong> <strong>2014</strong> 127<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Inventiva SAS, <strong>H1</strong> <strong>2014</strong> 128<br />
Assessment by Monotherapy Products, <strong>H1</strong> <strong>2014</strong> 129<br />
Assessment by Combination Products, <strong>H1</strong> <strong>2014</strong> 130<br />
Number of Products by Stage and Target, <strong>H1</strong> <strong>2014</strong> 133<br />
Number of Products by Stage and Mechanism of Action, <strong>H1</strong> <strong>2014</strong> 139<br />
Number of Products by<br />
List of Figures<br />
Number of Products under Development for <strong>Schizophrenia</strong>, <strong>H1</strong> <strong>2014</strong> 25<br />
Number of Products under Development for <strong>Schizophrenia</strong> - Comparative Analysis, <strong>H1</strong> <strong>2014</strong> 26<br />
Number of Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> 27<br />
Number of Products under Investigation by Universities/Institutes, <strong>H1</strong> <strong>2014</strong> 34<br />
Comparative Analysis by Late Stage Development, <strong>H1</strong> <strong>2014</strong> 36<br />
Comparative Analysis by Clinical Stage Development, <strong>H1</strong> <strong>2014</strong> 37<br />
Comparative Analysis by Early Stage Products, <strong>H1</strong> <strong>2014</strong> 38<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
Comparative Analysis by Unknown Stage Development, <strong>H1</strong> <strong>2014</strong> 39<br />
Assessment by Monotherapy Products, <strong>H1</strong> <strong>2014</strong> 129<br />
Number of Products by Top 10 Target, <strong>H1</strong> <strong>2014</strong> 131<br />
Number of Products by Stage and Top 10 Target, <strong>H1</strong> <strong>2014</strong> 132<br />
Number of Products by Top 10 Mechanism of Action, <strong>H1</strong> <strong>2014</strong> 137<br />
Number of Products by Stage and Top 10 Mechanism of Action, <strong>H1</strong> <strong>2014</strong> 138<br />
Number of Products by Top 10 Route of Administration, <strong>H1</strong> <strong>2014</strong> 144<br />
Number of Products by Stage and Top 10 Route of Administration, <strong>H1</strong> <strong>2014</strong> 145<br />
Number of Products by Top 10 Molecule Type, <strong>H1</strong> <strong>2014</strong> 147<br />
Number of Products by Stage and Top 10 Molecule Type, <strong>H1</strong> <strong>2014</strong> 148<br />
Related reports:<br />
Garden Fresh Restaurant Corp: Foodservice - Company Profile and SWOT Report<br />
BUCA, Inc. (Foodservice): Foodservice - Company Profile and SWOT Report<br />
Healthcare and Medical <strong>Market</strong> <strong>Research</strong><br />
About <strong>JSB</strong> <strong>Market</strong> <strong>Research</strong>:-<br />
<strong>JSB</strong> market research is a leading player in the market of research report distribution. It is<br />
one-stop-shop for all information related to market research for any sector of the industry.<br />
Along with providing in-depth analysis though reports, <strong>JSB</strong> market research also provides<br />
regular updates of the market though newsletters. Our reports are a well-researched work of<br />
market researchers with an extensive knowledge and a good level of market experience.<br />
To know more on <strong>Schizophrenia</strong> - <strong>Pipeline</strong> <strong>Review</strong>, <strong>H1</strong> <strong>2014</strong><br />
http://www.jsbmarketresearch.com/healthcare-medical/r-<strong>Schizophrenia</strong>-<strong>Pipeline</strong>-<strong>Review</strong>-<br />
118888<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
Change language